A
40.61
1.36 (3.46%)
| 前收盘价格 | 39.25 |
| 收盘价格 | 39.35 |
| 成交量 | 742,558 |
| 平均成交量 (3个月) | 735,520 |
| 市值 | 2,359,501,824 |
| 市盈率 (P/E TTM) | 3.60 |
| 价格/销量 (P/S) | 53.92 |
| 股市价格/股市净资产 (P/B) | 1.60 |
| 52周波幅 | |
| 利润日期 | 30 Oct 2025 |
| 营业毛利率 | 1,798.26% |
| 营业利益率 (TTM) | -1,221.97% |
| 稀释每股收益 (EPS TTM) | 11.54 |
| 季度收入增长率 (YOY) | 6.60% |
| 总债务/股东权益 (D/E MRQ) | 3.61% |
| 流动比率 (MRQ) | 18.50 |
| 营业现金流 (OCF TTM) | -401.46 M |
| 杠杆自由现金流 (LFCF TTM) | -237.66 M |
| 资产报酬率 (ROA TTM) | -22.88% |
| 股东权益报酬率 (ROE TTM) | 60.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Agios Pharmaceuticals, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.7
| 分析师共识 | 1.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.70 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.65% |
| 机构持股比例 | 101.39% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 65.00 (Scotiabank, 60.06%) | 购买 |
| 中 | 56.00 (37.90%) | |
| 低 | 51.00 (B of A Securities, 25.59%) | 购买 |
| 平均值 | 57.33 (41.17%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 39.16 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Sep 2025 | 56.00 (37.90%) | 购买 | 40.61 |
| Scotiabank | 28 Jul 2025 | 65.00 (60.06%) | 购买 | 37.20 |
| B of A Securities | 22 Jul 2025 | 51.00 (25.58%) | 购买 | 39.66 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| SCADDEN DAVID | - | 39.27 | -200 | -7,854 |
| 累积净数量 | -200 | |||
| 累积净值 ($) | -7,854 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 39.27 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| SCADDEN DAVID | 董事 | 27 Aug 2025 | 自动卖出 (-) | 200 | 39.27 | 7,854 |
| SCADDEN DAVID | 董事 | 27 Aug 2025 | 执行期权 | 200 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合